Skip to main content
Fig. 1 | Child and Adolescent Psychiatry and Mental Health

Fig. 1

From: A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Fig. 1

A ADHD symptoms and B functionality while receiving GXR: overall and by therapy type (monotherapy or adjunctive therapy). Symptoms and functionality assessed in the overall population was the primary analysis; assessment by therapy type was a post-hoc analysis. Best symptom response while on treatment with GXR was reported. Data for ADHD symptom assessment were derived from ADHD rating scales for 313 patients and from clinical notes for 17 patients. Data for ADHD functional assessment were derived from ADHD rating scales for 309 patients and from clinical notes for 21 patients. Adjunctive therapy was defined as patients receiving concomitant pharmacologic ADHD treatments. Percentages are based on the total number of enrolled patients. Due to missing values (≥ 6 months’ follow-up was required for inclusion in the study; patients may have discontinued between months 6 and 12), percentages in each category do not add up to 100%. ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release

Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000